MBX生物科学的新药物显示,治疗产后低血糖有希望,但尽管试验结果良好,其库存却有所下降。 MBX Biosciences' new drug shows promise for treating post-bariatric hypoglycemia, but its stock dropped despite positive trial results.

MBX Biosciences 报告了其 GLP-1 受体拮抗剂 MBX 1416 的 1 期阳性结果，表明其耐受性良好，并且在治疗减重后低血糖 （PBH） 方面具有良好的安全性。 MBX Biosciences reported positive Phase 1 results for its GLP-1 receptor antagonist, MBX 1416, showing it is well-tolerated and has a promising safety profile for treating post-bariatric hypoglycemia (PBH). 尽管试验结果良好,但公司股票在市场前贸易中下跌了7.3%。 Despite the positive trial outcomes, the company's stock fell 7.3% in pre-market trading. MBX生物科学公司计划在2025年年中与林业发展局会晤,并打算在今年晚些时候开始第2阶段试验。 MBX Biosciences plans to meet with the FDA in mid-2025 and aims to start Phase 2 trials later this year.